Anti-THSD7A IFA - Increased serological hit-rate in primary membranous nephropathy (MN)

Antibodies against phospholipase A2 receptor (anti-PLA2R antibodies) are the first and most important biomarker for autoimmune/primary MN and are detected in 75% in the sera of patients with primary MN, on average.

In the remaining 25%, autoantibodies against thrombospondin type 1 domain containing 7A (anti-THSD7A antibodies) are found in up to 14%. Autoantibodies against PLA2R and THSD7A only rarely occur in parallel. Consequently, a two-step strategy where anti-PLA2R-seronegative patients are tested for autoantibodies against THSD7A significantly improves the serological hit rate.

EUROIMMUN’s novel Anti-THSD7A IFA is the first standardised test system for the detection of autoantibodies against podocyte surface antigen THSD7A, and now available for you. The IFA is based on recombinant cells which express THSD7A heterologously.

It is an ideal supplementary test for Anti-Phospholipase A2 receptor (PLA2R) IIFT and is also suited for screening of patients with suspected primary MN. The IFA allows the qualitative and semi-quantitative determination of anti-THSD7A antibodies. Since these are specific for primary MN, the determination of THSD7A antibodies is also suitable for differentiation of primary and secondary MN.